Want to dodge some competition for your fast-growing products? Buy it up. That's the tack Shire took Monday, agreeing to shell out $5.9 billion for Massachusetts-based Dyax. The company boasts on-the-market Kalbitor, an acute treatment for hereditary angioedema (HAE), as well as the Phase III-ready candidate DX-2930, which bears the FDA's fast track and breakthrough tags, as well as orphan drug designations in both the U.S. and EU.
Shire signed a deal to buy Dyax for $5.9 billion, planning to snatch up a smaller competitor and fortify its rare disease business without taking its eyes off of acquisition target Baxalta.
The FDA has conferred its coveted breakthrough-therapy designation to Dyax's lead pipeline asset, an antibody designed to treat flare-ups of the rare hereditary angioedema.
GE Healthcare continues its quest to grab more genomic sequencing business, this time by snatching up contract genomic researcher SeqWright.
GE Healthcare is upping its game in a bid to develop new, targeted molecular diagnostics.
Cubist Pharmaceuticals is shelving its program for ecallantide, a once promising therapy for reducing blood loss in surgery, and axing its development deal on the drug with Dyax. The troubled program
Dyax shares rocketed up 38 percent yesterday evening after the developer announced that the FDA had approved its lead drug Kalbitor (also known as ecallantide or DX-88) for patients with hereditary
Cambridge, MA-based Dyax has grown a lot closer to Sanofi-Aventis in recent weeks. Sanofi-Aventis' previously announced deal to buy Fovea Pharmaceuticals for $540 million has positioned the pharma
Facing an FDA delay on its lead therapy, Dyax got out the budget-cutting axe and chopped 60 jobs as it scrambled to conserve cash. The layoffs, which will cut more than a third of its staff, should
Shares of Dyax took a beating today as the FDA refused to approve DX-88, the company's treatment for hereditary angioedema (HAE) attacks. HAE is a genetic disease that causes acute episodes of